These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation. Schwab AJ; Ebert AD Stem Cell Reports; 2015 Dec; 5(6):1039-1052. PubMed ID: 26651604 [TBL] [Abstract][Full Text] [Related]
4. Neurite Collapse and Altered ER Ca Korecka JA; Talbot S; Osborn TM; de Leeuw SM; Levy SA; Ferrari EJ; Moskites A; Atkinson E; Jodelka FM; Hinrich AJ; Hastings ML; Woolf CJ; Hallett PJ; Isacson O Stem Cell Reports; 2019 Jan; 12(1):29-41. PubMed ID: 30595548 [TBL] [Abstract][Full Text] [Related]
5. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749 [TBL] [Abstract][Full Text] [Related]
6. Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation. Bono F; Mutti V; Devoto P; Bolognin S; Schwamborn JC; Missale C; Fiorentini C Neurobiol Aging; 2021 Mar; 99():65-78. PubMed ID: 33422895 [TBL] [Abstract][Full Text] [Related]
7. In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation. Chang KH; Huang CY; Ou-Yang CH; Ho CH; Lin HY; Hsu CL; Chen YT; Chou YC; Chen YJ; Chen Y; Lin JL; Wang JK; Lin PW; Lin YR; Lin MH; Tseng CK; Lin CH Stem Cell Res Ther; 2021 Sep; 12(1):508. PubMed ID: 34551822 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Su YC; Qi X Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973 [TBL] [Abstract][Full Text] [Related]
9. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity. Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998 [TBL] [Abstract][Full Text] [Related]
10. Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient-derived induced pluripotent stem cells. Son MY; Sim H; Son YS; Jung KB; Lee MO; Oh JH; Chung SK; Jung CR; Kim J Neuropathol Appl Neurobiol; 2017 Dec; 43(7):584-603. PubMed ID: 28235153 [TBL] [Abstract][Full Text] [Related]
11. In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson's Disease in Common Marmosets. Vermilyea SC; Babinski A; Tran N; To S; Guthrie S; Kluss JH; Schmidt JK; Wiepz GJ; Meyer MG; Murphy ME; Cookson MR; Emborg ME; Golos TG Sci Rep; 2020 Feb; 10(1):3447. PubMed ID: 32103062 [TBL] [Abstract][Full Text] [Related]
13. A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. Dusonchet J; Kochubey O; Stafa K; Young SM; Zufferey R; Moore DJ; Schneider BL; Aebischer P J Neurosci; 2011 Jan; 31(3):907-12. PubMed ID: 21248115 [TBL] [Abstract][Full Text] [Related]
14. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001 [TBL] [Abstract][Full Text] [Related]
15. Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease. Huang L; Shimoji M; Wang J; Shah S; Kamila S; Biehl ER; Lim S; Chang A; Maguire-Zeiss KA; Su X; Federoff HJ Neurotherapeutics; 2013 Oct; 10(4):840-51. PubMed ID: 23963789 [TBL] [Abstract][Full Text] [Related]